ArticleAnnals of oncology : official journal of the European Society for Medical Oncology2022

Validation of cancer-type-dependent benefit from immune checkpoint blockade in TMB-H tumors identified by the FoundationOne CDx assay.

D J McGrail et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.